Hypervision Surgical raises £17m to reduce surgical leaks with hyperspectral imaging
This article covers Hypervision Surgical, a healthtech startup spun out of King’s College London, and its oversubscribed £17m Series A growth funding round to commercialise its hyperspectral imaging platform for surgery. The proceeds will fund wider clinical deployment of the HYPERSNAP system, development of a next-generation spectral sensor with imec and scaling of cloud-enabled AI analytics to provide surgeons with quantitative intraoperative tissue physiology metrics.
Hypervision Surgical, a healthtech startup spun out of King’s College London, has closed an oversubscribed £17 million growth funding round to commercialise its hyperspectral imaging platform for surgery. The company announced the raise as a Series A; the proceeds will fund wider clinical deployment of its HYPERSNAP system, advance a next‑generation spectral sensor co‑developed with imec, and scale its cloud‑enabled AI analytics.
Why it matters
Surgical teams still rely largely on subjective visual judgement for crucial intraoperative decisions such as where to transect bowel during colorectal surgery. Hypervision’s platform aims to provide objective, pixel‑level measures of tissue physiology — notably tissue oxygenation (StO₂) — without contrast dyes. That capability targets a recognised clinical problem: anastomotic leaks occur in up to 15% of colorectal procedures and are linked to worse outcomes, emergency reinterventions, longer ICU stays and high costs per case. A sensor that provides continuous, quantitative perfusion data at the point of surgery could change intraoperative decision making and potentially reduce those complications.
The funding also matters because the company already holds UK certification and US FDA clearance for open and minimally invasive general surgery, and the FDA created a new product code recognising AI/ML‑based real‑time video augmentation in imaging systems — a regulatory signal that could influence other surgical imaging developers.
Inside the product
Hypervision’s core technology, branded Hyperspectral Intelligence, combines an on‑chip spectral sensor, AI analytics and a cloud‑scalable architecture. The company says the spectral chip captures spectral signatures that are invisible to conventional cameras and that its software converts those signatures into real‑time, quantitative metrics such as StO₂ while preserving normal colour vision for surgeons.
The first commercial product, HYPERSNAP, runs inference at the edge on an NVIDIA IGX platform and is cleared for clinical use in the UK and US. HYPERSNAP is positioned for integration across open, laparoscopic, robotic and microscopic workflows and was selected for the FDA’s Safer Technologies Program (STeP). Early clinical evaluations in colorectal surgery are under way in the UK, with initial results accepted for presentation at the SAGES Annual Meeting.
Who are the investors?
The round was led by Heal Capital and included participation from Angelini Ventures, IP Group and Daycrest. Existing investors HERAN Partners, Redalpine, LifeX Ventures and ZEISS Ventures also invested. Strategic backers include the SINC Fund managed by SAGES Ingenuity, the for‑profit innovation arm of the Society of American Gastrointestinal and Endoscopic Surgeons, and UK cancer charity Macmillan Cancer Support. As part of the financing, industry veteran Rick Mangat — founder of NOVADAQ, whose fluorescence imaging business was acquired by Stryker — joins Hypervision’s board.
In the announcement, Christian Lautner, Founding Managing Partner, Heal Capital, said:
Surgical AI has made impressive progress using conventional cameras, but it ultimately faces a ceiling - it captures how tissue looks, not what is happening beneath the surface. Hypervision removes that limitation by delivering real-time, quantitative insights into tissue physiology at the pixel level. We believe this represents the sensing layer on which the next generation of surgical systems will be built - one that will make surgery measurably safer. That’s why we are proud to lead this round.
In the announcement, Steven D. Schwaitzberg, MD, President of SAGES Ingenuity, said:
The SAGES Investment Network Collaborative (SINC) is thrilled to have had the chance to review and join the investment opportunity that Hypervision represents. Enhancing the capabilities around non-contrast visualization is truly a step forward in smarter imaging.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
In the announcement, Michael Ebner, CEO and co‑founder of Hypervision Surgical, said:
This Series A marks a major milestone in our mission to power surgical intelligence through hyperspectral vision. By combining advanced spectral sensing with cloud-enabled AI analytics, we are building a new intelligence layer in surgery - giving surgeons real-time insights into tissue that were previously impossible to access.
Ebner and the company point to imec as a strategic partner for design, development and manufacturing of the next‑generation spectral sensor — a cross‑border R&D link intended to tighten hardware and software integration and lower per‑unit sensor costs as deployments scale.
The bigger picture
The deal highlights several threads in the UK and European healthtech scene: the continued emergence of university spinouts into clinical products; growing investor appetite for clinically focused imaging and AI that can demonstrate regulatory clearance; and cross‑border partnerships to manufacture specialised sensors. Hypervision’s clinical focus on colorectal surgery is one concrete use case, but the company aims to extend its sensing layer across many procedural settings if clinical results support broader adoption.
For the UK ecosystem, a King’s College London spinout securing strategic backing from both specialist healthcare VCs and surgical societies signals that investors and clinical bodies are willing to back technologies that bridge hardware innovation and AI. If Hypervision’s devices deliver on objective intraoperative metrics and integration with surgical workflows, the model could become a template for other clinical imaging startups seeking simultaneous regulatory and commercial traction across Europe and the US.
They've invested in Hypervision Surgical
Get to know these healthtech investors
| Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|
 Heal Capital | 4 investments investments | 8 contacts contacts | |||
 Angelini Ventures | 2 investments investments | more info | |||
 Ip Group | 9 investments investments | 2 contacts contacts | |||
 HERAN Partners | 4 investments investments | 7 contacts contacts | |||
 Redalpine | 12 investments investments | 1 contact contact | |||
 LifeX Ventures | 4 investments investments | 4 contacts contacts | |||
 ZEISS Ventures | 3 investments investments | more info | |||
 SINC Fund (SAGES Ingenuity) | 1 investment investment | more info |
Click here for a full list of 7,589+ startup investors in the UK